ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Modern Retina's® group editorial director, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
See more ASRS conference coverage here
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Recent Videos
Related Content
